Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/49621
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNarumol Silpa-archaen_US
dc.contributor.authorPenvadee Pattanaprichakulen_US
dc.contributor.authorNorramon Charoenpipatsinen_US
dc.contributor.authorNatchaya Jansuwanen_US
dc.contributor.authorSuthipol Udompunthuraken_US
dc.contributor.authorLeena Chularojanamontrien_US
dc.contributor.authorChanisada Wongpraparuten_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.date.accessioned2020-01-27T03:33:48Z-
dc.date.available2020-01-27T03:33:48Z-
dc.date.issued2020-01-01en_US
dc.identifier.citationPhotodermatology Photoimmunology and Photomedicine. Vol.36, No.1 (2020), 21-28en_US
dc.identifier.issn16000781en_US
dc.identifier.issn09054383en_US
dc.identifier.other2-s2.0-85077783053en_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/49621-
dc.description.abstract© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Background: Although ultraviolet A1 (UVA1) phototherapy is available for nearly 30 years, only few studies have been conducted for plaque-type psoriasis. Objectives: To determine the efficacy and safety of UVA1 phototherapy in psoriasis by assessing the clinical and histological outcomes. Methods: This open study enrolled 15 patients with moderate to severe plaque-type psoriasis. All of the patients had skin type IV. A whole-body UVA1 device consisting of 24 lamps, was irradiated at a medium dose of 50 J/cm2 three-times weekly for 30 sessions. Topical and systemic psoriasis treatments were discontinued before and during treatment; patients could only use emollients and antihistamines until 1-month post-completion. Psoriasis Area and Severity Index (PASI) scores were determined at baseline; at sessions 10th, 20th and 30th; and 1 month after treatment. Four-millimetre punch biopsies were obtained from the same psoriasis lesion at baseline and session 30th. Changes in histopathological gradings and polymorphonuclear, lymphocyte and Langerhans cell numbers were monitored. Results: Twelve patients completed the study. The mean age was 41.3 years (range: 25-71). The median PASI scores at baseline, session 30th and 1-month post-treatment were 16 (8.2, 43.3), 11 (4.4, 43.3) and 9.2 (2.7, 36.4), respectively. Although the PASI scores had improved significantly by 1-month post-treatment (P =.006), the histological parameters demonstrated minimal changes. All patients tolerated the phototherapy well and the most common side effect was skin tanning. Conclusions: While medium-dose UVA1 phototherapy demonstrated some efficacy in moderate to severe plaque-type psoriasis. However, it might not be an excellent choice.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85077783053&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleThe efficacy of UVA1 phototherapy in psoriasis: Clinical and histological aspectsen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1111/phpp.12498en_US
dc.identifier.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85077783053&origin=inwarden_US
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.